Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00095810 · ClinicalTrials.gov registry record · Phase 4

Aripiprazole in Patients With Psychosis Associated With Parkinson's Disease

A Phase 4 study of Parkinson's Disease and Psychoses, sponsored by Otsuka Pharmaceutical Development & Commercialization.

Completed
Registry status
Phase 4
Development phase
50
Enrollment target
1
Study location

NCT00095810 is a Phase 4 study of Parkinson's Disease and Psychoses that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 50 participants, below the 642-participant average among 156 other Parkinson's Disease trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00095810, a Phase 4 study of Parkinson's Disease and Psychoses, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.

COMPLETED
Registry status
Phase 4
Development phase
50 participants
Enrollment target
1
Study location

Study Summary

The purpose of this clinical research study is to assess the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease.

Conditions Studied

Parkinson's Disease Psychoses

Interventions

  • DRUG aripiprazole

Study Locations (1)

New York

  • Local Institution - Albany

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2003-07
Est. Completion 2004-09
Phase Phase 4

Sponsor

Otsuka Pharmaceutical Development & Commercialization

221 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00095810

The ClinicalTrials.gov registry entry for NCT00095810 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 642-participant average among 156 other Parkinson's Disease trials with a reported enrollment target (92% lower). The listed sponsor is Otsuka Pharmaceutical Development & Commercialization, which has 221 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Parkinson's Disease appearing as the primary indexed condition, and to 1 intervention - of which aripiprazole is the first listed.

NCT00095810 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT00095810 about?

NCT00095810 is a clinical study titled "Aripiprazole in Patients With Psychosis Associated With Parkinson's Disease". The purpose of this clinical research study is to assess the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease.

What is the current status of trial NCT00095810?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 50 participants. The study started on 2003-07. Estimated completion is 2004-09.

What conditions does trial NCT00095810 study?

This clinical trial studies the following conditions: Parkinson's Disease, Psychoses.

What interventions are being tested in trial NCT00095810?

The interventions under investigation include: aripiprazole (DRUG).

Who is sponsoring clinical trial NCT00095810?

This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00095810 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Parkinson's Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Parkinson's Disease

All registered trials for this condition

Psychoses

All registered trials for this condition

New York

All trials with a study site in New York

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.